<?xml version="1.0" encoding="UTF-8"?>
<ref id="ptr6802-bib-0008">
 <mixed-citation publication-type="journal" id="ptr6802-cit-0008">
  <string-name>
   <surname>Chen</surname>, 
   <given-names>C.‐N.</given-names>
  </string-name>, 
  <string-name>
   <surname>Lin</surname>, 
   <given-names>C. P. C.</given-names>
  </string-name>, 
  <string-name>
   <surname>Huang</surname>, 
   <given-names>K.‐K.</given-names>
  </string-name>, 
  <string-name>
   <surname>Chen</surname>, 
   <given-names>W.‐C.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hsieh</surname>, 
   <given-names>H.‐P.</given-names>
  </string-name>, 
  <string-name>
   <surname>Liang</surname>, 
   <given-names>P.‐H.</given-names>
  </string-name>, &amp; 
  <string-name>
   <surname>Hsu</surname>, 
   <given-names>J. T.‐A.</given-names>
  </string-name> (
  <year>2005</year>). 
  <article-title>Inhibition of SARS‐CoV 3C‐like protease activity by Theaflavin‐3,3′‐digallate (TF3)</article-title>. 
  <source xml:lang="en">Evidence‐Based Complementary and Alternative Medicine</source>, 
  <volume>2</volume>, 
  <fpage>209</fpage>–
  <lpage>215</lpage>. 
  <pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id>
  <pub-id pub-id-type="pmid">15937562</pub-id>
 </mixed-citation>
</ref>
